Finward Bancorp Purchases New Shares in BioNTech SE (NASDAQ:BNTX)

Finward Bancorp purchased a new stake in BioNTech SE (NASDAQ:BNTX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 2,965 shares of the company's stock, valued at approximately $338,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp raised its position in shares of BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after buying an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. raised its holdings in BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock valued at $88,000 after acquiring an additional 700 shares during the last quarter. Allianz SE purchased a new position in BioNTech in the 4th quarter worth approximately $90,000. GAMMA Investing LLC boosted its holdings in shares of BioNTech by 48.2% during the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company's stock worth $105,000 after purchasing an additional 300 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. purchased a new stake in shares of BioNTech in the fourth quarter valued at approximately $137,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Stock Up 0.5 %

NASDAQ BNTX traded up $0.51 during trading on Friday, reaching $98.76. 723,188 shares of the company's stock were exchanged, compared to its average volume of 858,489. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49. The stock has a market cap of $23.70 billion, a P/E ratio of -47.03 and a beta of 1.07. The company has a 50 day moving average price of $102.79 and a two-hundred day moving average price of $111.05.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter in the previous year, the firm earned $1.90 EPS. The company's revenue was down 19.5% compared to the same quarter last year. On average, equities research analysts anticipate that BioNTech SE will post -3.88 EPS for the current fiscal year.

Analyst Ratings Changes

BNTX has been the topic of a number of recent research reports. Canaccord Genuity Group reissued a "buy" rating and set a $171.44 price objective on shares of BioNTech in a research note on Tuesday, March 11th. Truist Financial initiated coverage on shares of BioNTech in a report on Friday, January 10th. They issued a "buy" rating and a $172.00 price objective for the company. BMO Capital Markets increased their price target on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. Citigroup began coverage on BioNTech in a research note on Thursday, March 13th. They issued a "buy" rating and a $145.00 price target on the stock. Finally, HC Wainwright lowered their price objective on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Three investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, BioNTech presently has an average rating of "Moderate Buy" and a consensus target price of $143.44.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.